Strong Clinical Growth and Improving Revenue Mix
Clinical subscription revenue grew 32% year-over-year; end-of-period Clinical subscribers grew 46% year-over-year and reached 197,000 (a 51% sequential increase). Management expects Clinical subscription revenue to comprise ~25%–30% of 2026 revenue, up from 16% in 2025.
Higher ARPU and Successful Upsell Dynamics
Overall Q1 ARPU increased 13% year-over-year to $20.59. Clinical ARPU remained over 4x higher than Behavioral ARPU; Core+ ARPU is nearly 2x Core. More than 20,000 existing Behavioral members upgraded to Clinical, and members who attend virtual experiences are 3–4x more likely to upgrade to Core+.
Clinical Outcomes and Program Effectiveness
Med+ members who regularly engaged in the GLP-1 success program lost 29.1% more body weight at 12 months vs non-engaged members. Company real-world data showed 19.4% weight loss at 12 months, supporting the combined clinical + behavioral offering as a competitive advantage.
High Adjusted Gross Margin and Cost Discipline
Adjusted gross margin remained near record highs at 73.6% in Q1. Adjusted SG&A was 15% of revenue and adjusted product development was 5% of revenue. Management highlighted structural margin improvements and cost actions, including exiting the corporate headquarters lease.
Reaffirmed Full-Year Guidance and Planned Debt Reduction
Management reaffirmed 2026 guidance: revenue $620M–$635M and adjusted EBITDA $105M–$115M, and expects to generate cash in 2026. Cash on hand was $121M at quarter end and the company plans a $37M cash utilization in Q2 to reduce term loan principal (expected to lower annualized interest by ~ $4M).
Core+ Engagement and Digital Offerings Momentum
Core+ subscribers reached 537,000, a 6% year-over-year increase. Virtual workshop attendance among Core+ members in the U.S. rose nearly 40% year-over-year, with growth in members attending multiple meetings per week and tailored programs (GLP-1 success, menopause) driving engagement and conversions.